[go: up one dir, main page]

WO2005023221A1 - Formulations de clarithromycine a biodisponibilite elevee - Google Patents

Formulations de clarithromycine a biodisponibilite elevee Download PDF

Info

Publication number
WO2005023221A1
WO2005023221A1 PCT/IB2004/002867 IB2004002867W WO2005023221A1 WO 2005023221 A1 WO2005023221 A1 WO 2005023221A1 IB 2004002867 W IB2004002867 W IB 2004002867W WO 2005023221 A1 WO2005023221 A1 WO 2005023221A1
Authority
WO
WIPO (PCT)
Prior art keywords
clarithromycin
pharmaceutical composition
composition according
polyethylene glycol
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/002867
Other languages
English (en)
Inventor
Pramod Kharwade
Rajeev Raghuvanshi
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2005023221A1 publication Critical patent/WO2005023221A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • An extended-release dosage form may improve the quality of therapy and the safety profile relative to a conventional dosage form. However, in order to be effective, these extended release formulations should completely release the drag within a predetermined period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le domaine technique de l'invention se rapporte à des compositions pharmaceutiques solides de clarithromycine, présentant des caractéristiques d'absorption et de dissolution améliorées, obtenues par la micronisation de la clarithromycine et d'un ou plusieurs agents mouillants.
PCT/IB2004/002867 2003-09-05 2004-09-03 Formulations de clarithromycine a biodisponibilite elevee Ceased WO2005023221A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1109DE2003 2003-09-05
IN1109/DEL/2003 2003-09-05

Publications (1)

Publication Number Publication Date
WO2005023221A1 true WO2005023221A1 (fr) 2005-03-17

Family

ID=34259943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002867 Ceased WO2005023221A1 (fr) 2003-09-05 2004-09-03 Formulations de clarithromycine a biodisponibilite elevee

Country Status (1)

Country Link
WO (1) WO2005023221A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2283824A1 (fr) * 2009-07-30 2011-02-16 Special Products Line S.p.A. Compositions et formules basées sur des matrices gonflables pour la libération prolongée de médicaments, comme clarithromycin, faiblement solubles
CN115350156A (zh) * 2022-08-26 2022-11-18 丽珠集团丽珠制药厂 一种克拉霉素片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022319A1 (fr) * 1994-02-16 1995-08-24 Abbott Laboratories Mode de preparation de formulations pharmaceutiques a fines particules
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
WO2000048607A1 (fr) * 1999-02-19 2000-08-24 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Matrice directement compressible pour liberation controlee de doses quotidiennes uniques de clarithromycine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022319A1 (fr) * 1994-02-16 1995-08-24 Abbott Laboratories Mode de preparation de formulations pharmaceutiques a fines particules
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
WO2000048607A1 (fr) * 1999-02-19 2000-08-24 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Matrice directement compressible pour liberation controlee de doses quotidiennes uniques de clarithromycine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2283824A1 (fr) * 2009-07-30 2011-02-16 Special Products Line S.p.A. Compositions et formules basées sur des matrices gonflables pour la libération prolongée de médicaments, comme clarithromycin, faiblement solubles
CN115350156A (zh) * 2022-08-26 2022-11-18 丽珠集团丽珠制药厂 一种克拉霉素片及其制备方法
CN115350156B (zh) * 2022-08-26 2023-11-28 丽珠集团丽珠制药厂 一种克拉霉素片及其制备方法

Similar Documents

Publication Publication Date Title
US20050163857A1 (en) Clarithromycin formulations having improved bioavailability
US20110008426A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
CN107666914A (zh) 帕博西尼的固体剂型
JP2009102341A (ja) コロイド状二酸化ケイ素を含んでなる医薬組成物
WO2009067557A1 (fr) Compositions pharmaceutiques de déférasirox
ZA200309289B (en) Oxcarbazepine dosage forms.
JP2001163769A (ja) シロスタゾール製剤
KR20040058189A (ko) 관능상 허용가능한 경구내 붕해 조성물
US20040115264A1 (en) Fenofibrate tablets
KR101828630B1 (ko) 구강 내 붕괴 정제
US10709699B2 (en) Pyridone derivative pharmaceutical composition and preparation method thereof
WO2009084041A2 (fr) Compositions pharmaceutiques de dexibuprofène
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
CN108420798A (zh) 一种抗凝剂的速释药物制剂及其制备方法
WO2004103346A1 (fr) Compositions pharmaceutiques a base d'acitretine
WO2005023221A1 (fr) Formulations de clarithromycine a biodisponibilite elevee
KR102489384B1 (ko) 생체이용율이 개선된 페노피브레이트 입자를 포함하는 약제학적 조성물
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
US20080206348A1 (en) Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers
CN116322657A (zh) 包括氘代丁苯那嗪的多颗粒剂型
KR102840220B1 (ko) 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
US20220241230A1 (en) Diclofenac sachet composition
KR20150096787A (ko) Ｎ-[5-[2-(3,5-디메톡시페닐)에틸]-2ｈ-피라졸-3-일]-4-[(3ｒ,5ｓ)-3,5-디메틸피페라진-1-일]벤즈아미드의 약학 제제
KR20010093186A (ko) 프로펜 함유 제약 혼합물
US20230390192A1 (en) Gastro retentive dosage forms comprising deutetrabenazine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1421/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase